Combined Modality Therapy for Unresectable Non-Small Cell Lung Cancer

Author:

Hazard Lisa J.,Sause W. T.

Publisher

Springer Berlin Heidelberg

Reference87 articles.

1. Agus DB, Bunn PA. et al. (2000) HER-2/neu as a therapeutic target in non-small cell lung cancer. prostate cancer. and ovarian cancer. Semin Oncol 27(Suppl 11):53–63

2. Akerley W, Herndon J, Turrisi A. et al. (2000) Induction chemotherapy with paclitaxel and carboplatin followed by concurrent thoracic radiation and weekly PC for patients with unresectable sectable stage III non-small cell lung cancer (NSCLC):preliminary analysis of a phase II trial by the CALGB. Proc Am Soc Clin Oncol 19:490a (Abstract 1915)

3. Albain JJ, Crowley AT, Turrisi DR. et al. (1997) Concurrent cisplatin/ etoposide plus radiotherapy (PE+RT) for pathologic stage (pathTN) IIIB non-small cell lung cancer (NSCLC): a South west Oncology Group (SWOG) phase II study (S9019). Proc Am Soc Clin Oncol 16: 446a (Abstract #1600)

4. Anderson H, Thatcher N, Walling J. et al. (1994) Gemcitabine and palliation of symptoms in non-small cell lung cancer. Proc Am Soc Clin Oncol 13: 367a (Abstract #1238)

5. Andre F, Grunewald D, Pignon JP, et al. (2000) Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications. J Clin Oncol 18:2981–2989

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3